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Abstract 
In recent decades, several biomarkers have been investigated as predictors of breast cancer risk, development, prognosis and treatment 
efficacy.
The detection of biomarkers strongly associated with breast carcinogenesis has an enormous potential, especially for selecting subjects 
at high risk of developing breast cancer who could benefit from chemopreventive treatments. 
Although the number of potential biomarkers continues to increase, a unique biomarker for breast cancer risk prediction has not been 
identified and it is probable that a panel of biomarkers will prove optimal. Further studies are needed to validate breast cancer biomarkers 
evaluation for individual risk assessment. 
This review summarizes the main biomarkers, which are important at different stages of breast carcinogenesis with updates from the 
recent literature. 
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Introduction 
Efficacy in breast cancer early diagnosis, treatment and 
prevention is a big challenge considering that breast cancer is 
the most common diagnosed cancer in women worldwide. 
Biomarkers have a critical role both in monitoring cancer 
progression and assisting the identification of high-risk subjects. 
The general characteristics of a biomarker should include high 
reproducibility and detectability, easy collection from patients by 
minimally invasive techniques and high correlation with the 
disease with different expression in healthy versus affected 
subjects. 
An ideal biomarker for monitoring cancer treatment should be 
strongly correlated with cancer growth and should be an index 
for drug efficacy. A good candidate biomarker for cancer 
prevention would be a marker directly correlated with risk and 
with molecular mechanisms of carcinogenesis in pre-cancerous 
tissues, should be differentially expressed in average versus 
high-risk populations and should predict response to 
chemopreventive agents. Several tumour markers have shown 
evidence of clinical usefulness and have been recommended 
for use in practice in breast cancer patients: CA 15-3, CA 27.29, 
carcinoembryonic antigen (CEA), oestrogen and progesterone 
receptors (ER, PR), human epidermal growth factor receptor 2 
(HER-2), urokinase plasminogen activator (uPA), plasminogen 
activator inhibitor 1 (PAI-1) and certain multiparametre gene 
expression assays (Oncotype DX, MammaPrint, Rotterdam 
Signature) [1]. 
In the last decade, much effort has been focused on discovering 
biomarkers that can be used to predict breast cancer risk. 
Among the established risk biomarkers, deleterious germline 
mutations in BRCA1/BRCA2/TP53 genes have been 
demonstrated as strong predictors of breast cancer 
development [2] and recent studies have also investigated the 
possible association between single nucleotide polymorphisms 
(SNPs) and breast cancer risk [3–5]. An association between 
levels of endogenous sex hormones with breast cancer risk 
have been shown in post-menopausal women [6,7], whereas 
other hormones and circulating biomarkers such as serum IGF-
1, IGFBP-3 and also testosterone have been demonstrated to 
be associated with risk, especially in pre-menopausal women, 
although more recent data have also demonstrated relevance in 
post-menopause [8–12]. 
Other potential biomarkers that have been investigated for an 
association with breast cancer include hormonal and nuclear 
receptors, membrane receptors and signal transduction factors, 
anti-inflammatory and antioxidant factors, apoptosis and 
angiogenesis factors, proliferation markers and antigens, 
epigenetic modulation factors, cellular inducible enzymes, cell 
cycle regulators, oncogenes and tumour suppressor genes 
[13,14]. 
In this review, we will discuss the main biomarkers which have 
been reported to have a role in breast cancer early development 
and progression. 
Hormonal and nuclear receptors 
Oestrogen and progesterone are essential hormones for breast 
growth, and their receptors (ER and PR) are established 
predictive factors for breast cancer treatment efficacy and 
disease outcome. ERs are transcription factors, which mediate 
the action of oestrogens, whereas the PR gene is regulated by 
oestrogen, and so the PR could be a marker of oestrogen action 
in breast cancer [15]. 
Previous studies have shown that ER and PR levels are 
associated with a favourable breast cancer prognosis and are 
highly predictive of benefit from endocrine treatment in both the 
adjuvant and metastatic settings [16-18]. Two different isoforms 
for each receptor have been described: ERa· and ERb; PRA 
and PRB. Functional experiments have demonstrated that ERa 
and ERb have completely different roles in breast cancer: ERa 
acts as a tumour promoter, whereas ERb is a tumour 
suppressor. The presence of ERb in breast tumours is 
associated with better prognosis and longer disease-free 
survival [19]. ERa expression has been demonstrated to be 
increased in normal epithelium taken from a tumour-bearing 
breast [20], and another study reported increased ERa 
expression in the tissue of women at high risk of developing 
breast cancer [21]. However, it is important to consider the 
relative amounts of ERa and ERb; as normal breast tissue 
becomes tumourigenic, the amount of ERa increases whereas 
the amount of ERb decreases [22]. 
In normal breast, PRA and PRB are co-expressed at similar 
levels on luminal epithelial cells, suggesting that both proteins 
are required to mediate physiologically relevant progesterone 
signalling, and an imbalance in the native ratio of the two 
isoforms may lead to alterations in PR signalling [23,24]. 
Previous studies have demonstrated that the ratio between PRA 
and PRB is altered during the breast carcinogenesis process 
[25,26]. 
Androgen receptors (AR) are expressed by the majority of 
human breast carcinomas, at a frequency comparable to or 
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higher than that reported for ER and PR [27,28]. AR shows a 
statistically significant association with important clinical and 
pathologic prognostic factors [29], such as histopathological 
grade, tumour invasiveness and axillary lymph node 
involvement [30-33]. Furthermore, some studies reported 
statistically significant associations between increased levels of 
testosterone and higher breast cancer risk in both pre- and 
post-menopausal healthy women [11,34–36], supporting a role 
for androgens and their receptors in breast carcinogenesis. 
All these findings highlight the role of ER, PR and AR in 
promoting breast cancer and consequently their potential as 
drug targets in both preventive and therapeutic settings. 
Other members of the steroid/thyroid hormone receptor super 
family include the nuclear retinoid receptors. Receptor selective 
retinoids inhibit the growth of both normal and cancerous 
human breast cells predominantly through induction of a G1 cell 
cycle block [37]. There are two classes of retinoid receptors: 
retinoic acid receptors (RARs) and retinoid X receptors (RXRs). 
Both types of receptors are encoded by three distinct genes a, b 
and g. Their functional activities require dimerisation with a 
member of the nuclear non-steroidal receptor family, in 
particular RXRs dimerise with peroxisome proliferator-activated 
receptors (PPARs) and with the vitamin D receptor (VDR) [38-
40]. 
The RARs and RXRs are thought to mediate the effects of 
retinoids on cell growth, differentiation and apoptosis and, 
therefore, to have a role in mammary carcinogenesis 
suppression [41–43]. RARa expression has been demonstrated 
to be positively linked to proliferative activity and to ER 
expression [44], whereas RARb may act as a tumour repressor 
gene, since its expression is progressively lost with increasing 
proliferative activity of the tumour [45]. Furthermore, an 
increasing RARa/RARb ratio may be a marker of progression 
from the pre-invasive to the invasive state in breast cancer [46]. 
The PPARs are also members of the nuclear receptor super 
family, which includes steroid, retinoid and thyroid hormone 
receptors [47,48]. Three isoforms of PPAR have been identified, 
a, d and g. PPARg has been found to be expressed in normal 
breast epithelium and breast cancers [49]. It heterodimerises 
with RXR and then binds to the peroxisome proliferator 
response elements in the promoter regions of targets genes, 
allowing for activation of gene transcription that is responsible 
for cell cycle modulation, cellular differentiation, decreased 
proliferation and inhibition of angiogenesis [50,51]. 
Previous studies suggested that PPARg signalling may 
exacerbate mammary gland tumour development in mice [52] 
and PPARg ligands have been shown to inhibit the proliferation 
and induce the apoptosis of breast cancer cell lines in vitro 
through the activation of PPARg [53]. Furthermore, a favourable 
impact of PPARg expression on disease-free survival of 
patients with ductal breast carcinoma, and its possible 
cooperation with ERb in exerting that favourable effect has been 
reported [54]. 
All these results document important roles for retinoid receptors 
and PPARs in oncogenesis, thereby identifying new targets for 
cancer therapy and prevention. Further evidence supporting the 
importance of the retinoid pathway in breast cancer 
development has been provided by a large randomised trial with 
the synthetic retinoid fenretinide that has shown a reduced risk 
of recurrence after primary surgery in pre-menopausal women 
[55]. 
The vitamin D receptor is a nuclear receptor present on over 
80% of human breast cancers and mediates the action of 1,25-
dihydroxy-vitamin D3, the biologically active form of vitamin D, 
that modulates differentiation, cell cycle and apoptosis of 
stromal and epithelial cells derived from mammary gland and 
breast cancers in vitro [56-60]. A vitamin D analogue 
significantly enhanced the ability of tamoxifen to prevent 
mammary tumours in rats, suggesting that vitamin D 
compounds and anti-oestrogenic compounds might protect 
against breast cancer through independent mechanisms [61]. 
The expression patterns of the heterodimers formed by VDR 
and RARs or RXRs have been studied by 
immunohistochemistry in benign and malignant human breast 
tissues. Higher levels of all receptor types were found in both in 
situ and infiltrative carcinomas compared to benign breast 
diseases or normal breast tissue [62,63]. Previous studies on 
VDR expression and its relationship with breast cancer 
prognosis indicated a longer disease-free survival in patients 
with VDR positive tumours compared to those with VDR 
negative neoplasms [60,64]. An inverse correlation between 
vitamin D intake and breast cancer risk has been observed in 
several studies [65–67] and also low serum 1,25-dihydroxy-
vitamin D3 has been correlated with increased breast cancer 
risk and metastasis [68,69]. 
Several epidemiologic, mechanistic and experimental data 
support the chemopreventive potential of vitamin D and its 
analogues, although hypercalcemic side effects represent a 
major obstacle to their clinical development. A proposed 
strategy for using a non-calcemic dose in the chemopreventive 
setting is to administer vitamin D or its analogues in 
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combinations with other agents, such as retinoids or anti-
oestrogenic compounds [70]. 
 
Membrane receptors and signal transduction factors 
Tyrosine kinase signalling has been demonstrated to have an 
important role in the genesis and progression of human breast 
cancer as well as in all the steps of the normal mammary gland 
development [71]. Receptor tyrosine kinases (RTK) belong to a 
class of transmembrane receptors composed of nearly 60 
members distributed among 20 subfamilies. A little more than 
half of the known RTKs have been repeatedly found in either 
mutated or over-expressed forms to be associated with human 
malignancies, including sporadic cases [72,73]. The most 
studied receptors of this super family are the human epidermal 
growth factor receptors, which belong to subclass I, comprising 
four members (HER1, HER2, HER3, HER4). The epidermal 
growth factor receptor (EGFR or HER1) has been demonstrated 
to be involved in malignant transformation and cancer 
progression and its over-expression in cancer tissues has been 
associated with a more aggressive phenotype and a worse 
survival [74,75]. Nearly 45% of human breast tumours express 
EGFR and previous studies reported an inverse correlation 
between EGFR and ER expression in breast cancer [76,77]. 
EGFR and ER are also frequently co-expressed in normal-
appearing cells obtained from breast cancer patients [78]. 
Moreover, Fabian et al found a significantly higher expression of 
EGFR in ductal cells of needle aspirates from women at high 
risk for breast cancer development than in low-risk control 
subjects [79], suggesting EGFR as a viable target for breast 
cancer chemoprevention. 
The HER2 gene is amplified and over-expressed in about 25% 
of breast cancers, conferring a more aggressive biology [80]. 
Over-expression of the HER2 gene is associated with rapid 
tumour growth, increased risk of recurrence after surgery, poor 
response to conventional chemotherapy and shortened survival 
[81]. 
It has been reported that tamoxifen treatment up-regulates 
HER2 by 40% in breast cancer cells expressing both HER2 and 
ER [82], and that when HER2 is co-expressed with ERa, the 
patients show a shorter disease-free survival and overall 
survival [83]. These findings suggest that HER2 modulation is 
an ER-mediated process. 
The other two members of the HER family, HER3 and HER4, 
are of particular interest because of their ability to interact 
directly with HER2. A recent study presented striking evidence 
that alterations in HER3 exist in breast cancer [84] and another 
study demonstrated that blocking HER2 resulted in anti-
proliferative effects accompanied by a decrease in HER3 
signalling activity [85]. Furthermore, HER3 contributes to HER2-
associated tamoxifen resistance and a decrease in HER3 levels 
restores sensitivity to tamoxifen [86] and gefitinib (an EGFR 
tyrosine kinase inhibitor) has been demonstrated to decrease 
EGFR and HER3 phosphorylation through the inhibition of 
EGFR/HER3 dimerisation [87]. HER4 protein over-expression 
has previously been described as a positive prognostic factor in 
breast tumours [88-90]. HER4 amplification detected by FISH 
was found to be correlated with a positive oestrogen receptor 
status [84,91], whereas conflicting conclusions were reported by 
other authors who found that HER4 amplification and ER 
activity were negatively correlated [92]. These differences may 
be due to the variable responses by HER4 to its activating 
ligand Heregulin, resulting in either proliferation or 
differentiation, and perhaps influenced by homodimerisation or 
heterodimerisation with other HER family members [93]. 
Two other membrane receptors demonstrated to have a role in 
breast carcinogenesis are the transforming growth factor beta 
(TGF-b) receptor and the insulin-like growth factor (IGF) 
receptors. TGF-b signalling pathway is implicated in cell 
senescence, regulation of cell growth and differentiation [94]. 
TGF-b has a dual role: in normal development, it inhibits cell 
proliferation by induction of apoptosis and cell cycle arrest and 
promotes cell differentiation, whereas during tumourigenesis 
TGF-b secreted from tumour cells often loses its inhibitory 
function in favour of its oncogenic activity [95]. Increased 
production of TGF-b occurs in different tumour types and 
correlates with the severity of the tumour grade [96,97]. Since 
the role of TGF-b pathway in carcinogenesis has been 
elucidated, specific molecular inhibitors, such as TGF-b 
antibodies and antisense oligonucleotides that block TGF-b 
receptor have been investigated in pre-clinical and clinical 
studies for cancer therapy [98,99]. Recent studies demonstrated 
the efficacy of TGF-b inhibitors in reducing the in vivo bone 
metastatic capacity of human breast cancer cells [100–102]. 
Another recent study reported that TGF-b is a potential mediator 
of retinoic acid and tamoxifen-induced apoptosis in breast 
cancer cell lines, suggesting that the TGF-b pathway may have 
a role also in the breast chemoprevention setting [103]. 
The IGFs are peptide hormones involved in regulation of cell 
proliferation, differentiation and apoptosis [104]. Several studies 
investigating the relationship between the circulating 
concentration of IGF-I and IGFBP-3 and breast cancer risk 
demonstrated a correlation between increasing IGF-I and 
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IGFBP-3 levels and increased breast cancer risk, especially in 
pre-menopausal [8–10] and more recently also in post-
menopausal women [12]. Anti-oestrogens, effective in breast 
cancer treatment and prevention, reduce serum IGF-I levels 
[105]. IGF-I receptors are over-expressed in many breast 
cancers [106], and recent clinical trials have investigated the 
effectiveness of IGF-I receptor inhibitors in cancer therapy 
[107]. Circulating IGF-I mainly binds to IGFBP-3, a protein that 
regulates the mitogenic actions of IGFs and inhibits their 
apoptotic effect and also has an IGF-independent inhibitory 
effect on cell growth [104]. Baxter and co-worker showed that 
IGFBP-3 production is potently induced by TGF-b and proposed 
a role for IGFBP-3 in mediating TGF-b inhibitory activity 
[108,109]. IGFBP3 is also a ligand for the nuclear RXR-a 
receptor, which was shown to be necessary for IGFBP-3 
induced apoptosis [110]. Results from a phase III breast cancer 
prevention trial with fenretinide, suggested that the reduction of 
IGF-I and IGFBP-3 levels may in part explain the cancer risk 
reduction observed in women <50 years of age [111]. 
Inflammation and oxidation markers 
Cyclooxygenase-2 (COX-2) is an important inflammatory 
mediator, responsible for the conversion of arachidonic acid into 
prostaglandins. In the last decade, several studies reported a 
correlation between COX-2 expression and breast cancer. 
Elevated COX-2 protein levels have been detected in 
approximately 40% of invasive breast cancers and COX-2 over-
expression has been demonstrated to correlate with large 
tumour size, high grade, high proliferation, hormone receptor 
negative status and over-expression of HER-2 [112–117]. The 
role of COX-2 in breast cancer pathogenesis suggested the 
COX-2 signalling as a target for breast cancer treatment and 
prevention. Some meta-analyses and case control studies 
reported a moderate reduction in risk of breast cancer, up to 
24%, with non-steroidal anti-inflammatory drugs (NSAIDs) [118–
120]. Pre-clinical studies suggested that celecoxib, which is a 
selective inhibitor of COX-2, is effective in both preventing and 
treating breast cancer in a dose-dependent manner [121,122]. 
However, other trials have identified an increased 
cardiovascular risk associated with COX inhibitors, probably 
due to their selective depression of prostacyclin levels [123]. 
Sauter  et al investigated the possible correlation between 
celecoxib administration and prostaglandin concentration in 
serum and nipple aspirate fluid (NAF), reporting a reduction of 
prostaglandin levels in NAF of post-menopausal high-risk 
women and a reduction in both NAF and plasma prostaglandin 
levels in women with newly diagnosed breast cancer [124]. 
Further clinical trials are necessary to better understand the 
chemopreventive and treatment potential of celecoxib. 
Matrix metalloproteinases (MMPs) are a family of proteases 
involved in the regulation of the cell microenvironment, matrix 
turnover, growth factor bioavailability and several aspects of 
immunity and inflammation. Other classes of proteases, which 
interact with MMPs are a disintegrin and metalloproteinases 
(ADAMs), and tissue inhibitor of metalloproteinases (TIMPs) 
[125,126]. Epidemiological evidence suggests an association 
between inflammation and breast cancer and several studies 
investigating the role for MMPs, ADAMs and TIMPs in breast 
cancer risk and progression have demonstrated that high levels 
of MMP9 are associated with poor breast cancer prognosis 
[127,128]. MMP1 may prove be a breast cancer risk marker 
since it has been found in tissues with atypical ductal 
hyperplasia and in ductal lavage cells from patients at risk for 
developing breast cancer [129]. Other studies reported that 
TIMP1 levels correlate positively with higher serum HER-2 
levels, increased metastasis and reduced survival in breast 
cancer patients [130], whereas TIMP3 over-expression was 
associated with successful adjuvant endocrine therapy, good 
prognosis and longer disease-free survival [131–133]. Some 
evidence also suggests a role for TIMP3 as a breast cancer risk 
marker as TIMP3 levels were higher in mammographically 
dense breasts, which are considered to be at higher risk for 
developing breast cancer [134]. Although the biology of ADAMs 
is less understood than that of MMPs, several components of 
this family have been found in breast cancer and, in particular, 
ADAM9 correlates positively with HER-2 levels [135] and with 
positive response to tamoxifen [136]. Furthermore, ADAM12 
urine levels have been found to positively correlate with breast 
cancer progression, suggesting a possible diagnostic role [136]. 
C-reactive protein (CRP) is an acute-phase protein, synthesized 
in the liver, which is considered a marker of inflammation [137]. 
CRP serum levels have been associated with breast cancer and 
increased circulating levels of CRP have also been detected in 
more advanced stages of breast malignancy [138], suggesting 
the potential use of CRP as a biomarker of disease prognosis 
[139]. Elevated levels of CRP are associated with reduced 
survival in breast cancer patients [140–142]. In the Rotterdam 
Study, a statistically significant increase in breast cancer risk 
associated with higher CRP levels at baseline was reported 
[143], whereas other authors did not find any significant 
association between circulating CRP and breast cancer risk 
[144–146]. In a recent study, the relation between the level of 
CRP protein in NAF and breast cancer risk as predicted by the 
Gail model was investigated. CRP was found in NAF samples, 
and it was not significantly related to serum CRP levels, 
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suggesting that CRP presence in NAF may reflect the early 
development of proliferative changes in the ductal epithelium 
preceding carcinoma in situ and invasive carcinoma [147]. 
Osteopontin (OPN) is a phosphoglycoprotein involved in a 
variety of physiopathologic processes such as bone 
remodelling, angiogenesis, inflammatory response, cell growth 
and tissue differentiation and wound healing [148]. OPN 
positivity of the primary breast tumour is significantly associated 
with decreased survival [149,150] and recent studies by Mirza 
et al suggested that the OPN-c splice variant could be a 
selective and prognostic marker for human breast cancer, as 
OPN-c mRNA was identified in 80% of breast carcinomas [151]. 
Patani et al demonstrated a significant positive association of 
OPN-b and OPN-c expression with adverse pathological and 
clinical outcomes [152]. 
In a cohort of women with newly diagnosed metastatic breast 
cancer, high-baseline OPN plasma levels or OPN increase > 
250 ng/ml at any time during follow-up were found to be 
associated with poor survival [153] and higher OPN levels in 
patients with metastatic breast cancer may be associated with 
an increased number of involved sites and decreased survival 
[154]. 
Apoptosis, cell cycle regulators and angiogenesis 
factors 
The apoptosis-signalling pathway has an important role in 
cancer onset and progression. Many apoptotic proteins have 
been studied for an association with breast cancer 
pathogenesis. The inhibitors of apoptotic proteins are a more 
recently described family of proteins that function as 
endogenous inhibitors of caspases [155]. Survivin is the only 
member of this family, which has a dual role in inhibition of 
apoptosis and regulation of mitosis [156]. Data from a large 
analysis of human transcripts reported a higher expression of 
survivin in cancer tissues compared with normal tissues [157]. 
In an immunohistochemical study, survivin over-expression was 
detected in surgically resected primary tumour specimens of 
breast cancers [158], and recent studies reported that survivin is 
linked to aggressive breast cancers [159], resistance to 
apoptosis [160] and modulation of HER-2 signalling [161]. Few 
studies investigated the possible association between survivin 
and histological parameters or prognostic factors with 
controversial results: some of them reported no association 
between tissue and serum survivin expression and tumour size, 
p53 expression, oestrogen and progesteron receptors levels 
[162–164], while others showed that high-tissue survivin 
expression was correlated with high-nuclear grade, negative 
hormone receptor status and HER-2 over-expression [165], and 
that the presence of survivin is a highly significant independent 
predictor of shorter duration of survival in patients with poor 
prognostic features [166]. 
TP53 is a tumour suppressor gene that encodes the p53 
protein, which is activated in response to several forms of 
cellular stress and mediates many cellular processes, including 
cell cycle arrest, apoptosis, senescence and differentiation 
[167,168]. Several studies have investigated the predictive 
value of TP53 mutations for tumour response to treatment and 
patient outcome in various cancers and for breast cancer the 
presence of a mutation was reported to correlate with shorter 
survival or a poor outcome [169,170]. TP53 mutation status was 
also shown to be useful to identify women at higher risk of 
disease recurrence and death when their tumour had a HER2 
gene amplification [171]. 
P53 has been shown to be a possible target of the immune 
system. Antibodies against p53 have been detected in different 
types of malignant disease, with the highest positivity rates 
observed for breast cancer [172]. There are studies reporting a 
significant correlation between presence of p53 antibodies and 
the detection of mutated p53 protein in tissue sections and 
higher serum levels of antibodies in breast cancer cases than in 
healthy subjects from the general population. Furthermore, in 
breast cancer patients the presence of p53 antibodies also 
indicated a shortened survival [173–175]. 
Cyclin D1 is a key factor involved in the regulation of the G1-S 
phase transition during the cell cycle. Cyclin D1 over-expression 
has been observed in DCIS, suggesting a possible role in 
breast cancer development [176–178]. Previous studies have 
reported that in ER-positive breast cancer patients, cyclin D1 
over-expression is associated with overall and relapse-free 
survival [179,180]. 
It has been shown that cyclin D1 can activate oestrogen 
receptor transcriptional activity in the absence of estradiol, and 
that this activity can be inhibited by 4-hydroxytamoxifen [181]. 
Furthermore, published in vitro data suggested that retinoids 
reduce cyclin D1 expression in human breast cancer cell lines 
[182,183]. These data are of great interest, since fenretinide has 
shown to induce a significant risk reduction of second breast 
cancer in pre-menopausal women, suggesting a possible role 
as breast cancer chemopreventive agent in high-risk young 
women [184]. 
Vascular endothelial growth factor (VEGF) is a key enhancer 
factor of angiogenesis, the process of new blood vessels 
formation, involved in cancer development and progression. 
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Several studies have investigated the association between 
VEGF expression in cancer tissues and plasma with breast 
cancer. High levels of VEGF expression in breast cancer 
tissues have been associated with poor prognosis and 
decreased overall survival [185,186], and many authors have 
reported that circulating VEGF levels are increased among 
breast cancer women [187–189]. It has been suggested that 
VEGF expression may help predict the biologic aggressiveness 
of DCIS [190]. VEGF over-expression was found not only in 
DCIS, but also before remodelling of the fibroblastic stroma of 
pre-malignant breast lesions [191]. Furthermore, previous 
studies evaluating VEGF expression and angiogenesis in breast 
cancer patients, have reported that sex steroids regulate 
angiogenesis and increase VEGF expression [192], whereas 
the agonist of the oestrogen receptor tamoxifen has been 
shown to decrease VEGF expression and angiogenesis 
[187,189,193]. 
Proliferation markers and antigens 
Several studies have been conducted to investigate the 
possible use of proliferation markers as breast cancer 
prognostic indicators. Various methods are available for the 
measurement of proliferation rates in tumours, including mitotic 
counts, estimation of the fraction of cells in S-phase of the cell 
cycle and proliferation-associated antigens [194]. A previous 
study reported that mitotic count was a stronger predictor of 
survival than tumour size and lymphatic or skin invasion [195]. 
However, one limitation of mitotic index as a measure of 
proliferation is that the duration of the mitotic phase of the cell 
cycle is variable and consequently the correlation of number of 
mitoses and proliferation rate is not necessarily linear [196]. The 
measurement of the fraction of cells in chromosomal DNA 
synthesis (the S-phase of cell cycle) is one of the standard 
methods of assessing proliferation, with various techniques that 
can detect DNA replication. Recently, alternative methods of 
assessing proliferation that are based on the detection of 
nuclear antigens by immunohistochemistry have been 
investigated. Ki67, a protein expressed in the nucleus during the 
 cell cycle, is actually used as measure of proliferation [194]. It 
has been demonstrated that Ki67 correlates significantly with 
estimates of the mitotic count index and the measurement of the 
fraction of cells in S-phase [197,198]. Several studies reported 
an association between Ki67 and disease-free and overall 
survival, with an increased risk of recurrence in tumours with a 
high Ki67 [199–201]. Several authors measured Ki67 in 
tamoxifen-treated breast cancer patients, all reporting a 
decrease in Ki67 [202–204]. Ki67 has been validated as a 
surrogate endpoint biomarker reflecting the superiority of 
anastrozole versus tamoxifen in early stage breast cancer, with 
a greater reduction in Ki67 being achieved with anastrozole 
[205]. In recent studies, Ki67 was measured either in random 
periareolar fine needle aspiration and in ductal lavage samples 
from women at high risk of developing breast cancer, and it was 
reported a significant association between Ki67 expression and 
atypia and cell yield, indicating Ki67 as a surrogate biomarker in 
early-phase chemoprevention trials [206,207]. 
Proliferating cell nuclear antigen (PCNA), a nuclear protein 
involved in DNA repair processes, has been investigated, but 
appear to correlate poorly with Ki67 and mitotic count, 
suggesting a more limited use in assessing proliferation [208]. 
 
Conclusions 
The biomarkers that have been discussed in this review are 
involved at different stages of the breast carcinogenesis multi-
step process. Each of the described biomarkers may be a target 
for drug treatment or prevention. Notwithstanding, we should 
take into account that the absolute benefit of a treatment varies 
greatly between individuals. Biomarkers may also be helpful for 
identification of high-risk subjects who will benefit from a given 
treatment. However, the currently available data do not support 
the implementation of a cancer risk model based on biomarkers 
evaluation. Further studies and prospective clinical randomised 
trials are necessary to better define whether and which 
biomarkers could be used in clinical practice for better treatment 
selection and patient follow-up. 
 
 
 
 
 7  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
References 
1.  Harris L, Fritsche H, Mennel R, Norton L, Ravdin P et al 
(2007)  American Society of Clinical Oncology 2007 
update of recommendations for the use of tumour 
markers in breast cancer  J Clin Oncol  25  5287–5312. 
PMID: 17954709  doi:10.1200/JCO.2007.14.2364 
2.  Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE et 
al (2003) Average risks of breast and ovarian cancer 
associated with BRCA1 or BRCA2 mutations detected 
in case Series unselected for family history:a 
combined analysis of 22 studies  Am J Hum Genet 
721117–1130. PMID: 12677558  doi:10.1086/375033 
3.  Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison 
J  et al (2008) Heterogeneity of breast cancer 
associations with five susceptibility loci by clinical and 
pathological characteristics  PLoS  Genet  4:e1000054 
PMID: 18437204  doi:10.1371/journal.pgen.1000054 
4.  Easton DF, Pooley KA, Dunning AM, Pharoah PD, 
Thompson D et al (2007) Genome-wide association 
study identifies novel breast cancer susceptibility loci 
Nature  447 1087–1093  PMID: 17529967  doi:10.1038/ 
nature05887 
5.  Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, 
Reed MW et al (2007) A common coding variant in 
CASP8 is associated with breast cancer risk Nat Genet 
39 352–358 PMID: 17293864 doi:10.1038/ng1981 
6.  Yager JD and Davidson NE (2006) Estrogen 
carcinogenesis in breast cancer N Engl J Med 354 270–
282 PMID: 16421368  doi:10.1056/NEJMra050776 
7.  Key T, Appleby P, Barnes I and Reeves G (2002) 
Endogenous sex hormones and breast cancer in 
postmenopausal women:reanalysis of nine prospective 
studies J Natl Cancer Inst 94 606–616 PMID: 11959894 
8.  Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud 
DS, Deroo B, Rosner B, Speizer FE and Pollak M (1998) 
Circulating concentrations of insulin-like growth factor-
I and risk of breast cancer Lancet 351 1393–1396 PMID: 
9593409 doi:10.1016/S0140-6736(97)10384-1 
9.  Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet 
SM and Egger M (2004) Insulin-like growth factor (IGF)-I, 
IGF binding protein-3, and cancer risk:systematic 
review and meta-regression analysis Lancet 363 1346–
1353 PMID: 15110491 doi:10.1016/S0140-6736(04)16044-
3 
10.  Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM et 
al (2005) Polymorphisms and circulating levels in the 
insulin-like growth factor system and risk of breast 
cancer:a systematic review  Cancer Epidemiol 
Biomarkers Prev 14 2–19 PMID: 15668470 
11.  Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, 
Venturelli E, Sieri S, Pala V and Berrino F (2004) 
Endogenous sex hormones and subsequent breast 
cancer in premenopausal women Int J Cancer 112 312–
318 PMID: 15352045 doi:10.1002/ijc.20403 
12.  Barnes BB, Chang-Claude J, Flesch-Janys D, Kinscherf R, 
Schmidt M, Slanger T, Bonaterra G and Steindorf K (2009) 
Cancer risk factors associated with insulin-like growth 
factor (IGF)-I and IGF-binding protein-3 levels in 
healthy women:effect modification by menopausal 
status Cancer Causes Control PMID: 19597750 
13.  Janssens JP, Verlinden I, Gungor N, Raus J and Michiels L 
(2004) Protein biomarkers for breast cancer prevention 
Eur J Cancer Prev  13 307–317  PMID: 15554559  
doi:10.1097/01.cej.0000136568.86245.b7 
14.  Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, 
Pearce HL et al (2006) Progress in chemoprevention 
drug development:the promise of molecular 
biomarkers for prevention of intraepithelial neoplasia 
and cancer--a plan to move forward Clin Cancer Res 12 
3661–3697 PMID: 16778094  doi:10.1158/1078-0432.CCR-
06-1104 
15.  Horwitz KB, McGuire WL. (1975) Predicting response to 
endocrine therapy in human breast cancer:a 
hypothesis. Science 189:726–727.  PMID: 168640 
doi:10.1126/science.168640 
16.  Clark GM, McGuire WL, Hubay CA, Pearson OH, Carter 
AC. (1983) The importance of estrogen and 
progesterone receptor in primary breast cancer. Prog 
Clin Biol Res 132E:183–190. PMID: 6647468 
17.  (2005) Effects of chemotherapy and hormonal therapy 
for early breast cancer on recurrence and 15-year 
survival:an overview of the randomised trials  Lancet 
365  1687–1717  PMID: 15894097  doi:10.1016/S0140-
6736(05)66544-0 
18.  Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C et al 
(1992)  Prognostic significance of progesterone 
receptor levels in estrogen receptor-positive patients 
with metastatic breast cancer treated with 
tamoxifen:results of a prospective Southwest 
Oncology Group study J Clin Oncol 10 1284–1291 PMID: 
1634918 
19.  Chen GG, Zeng Q and Tse GM (2008) Estrogen and its 
receptors in cancer  Med Res Rev  28 954–974  PMID: 
18642351  doi:10.1002/med.20131 
20.  Khan SA, Rogers MA, Obando JA and Tamsen A (1994) 
Estrogen receptor expression of benign breast 
epithelium and its association with breast cancer 
Cancer Res 54 993–997. PMID: 8313390 
21.  Lawson JS, Field AS, Champion S, Tran D, Ishikura H and 
Trichopoulos D (1999) Low oestrogen receptor alpha 
 8  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
expression in normal breast tissue underlies low 
breast cancer incidence in Japan Lancet 354 1787–1788 
PMID: 10577642  doi:10.1016/S0140-6736(99)04936-3 
22.  Leygue E, Dotzlaw H, Watson PH and Murphy LC (1998) 
Altered estrogen receptor alpha and beta messenger 
RNA expression during human breast tumourigenesis 
Cancer Res 58 3197–3201 PMID: 9699641 
23.  Shyamala G, Yang X, Cardiff RD and Dale E (2000) 
Impact of progesterone receptor on cell-fate decisions 
during mammary gland development Proc Natl Acad Sci 
USA 97 3044–3049 PMID: 10737785  doi:10.1073/pnas.97. 
7.3044 
24.  McGowan EM and Clarke CL (1999) Effect of 
overexpression of progesterone receptor A on 
endogenous progestin-sensitive endpoints in breast 
cancer cells  Mol Endocrinol  13  1657–1671  PMID: 
10517668  doi:10.1210/me.13.10.1657 
25.  Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, 
Bilous AM and Clarke CL (1995) Characterization of 
progesterone receptor A and B expression in human 
breast cancer Cancer Res 55 5063–5068 PMID: 7585552 
26.  Mote PA, Bartow S, Tran N and Clarke CL (2002) Loss of 
co-ordinate expression of progesterone receptors A 
and B is an early event in breast carcinogenesis Breast 
Cancer Res Treat  72 163–172  PMID: 12038707   
doi:10.1023/A:1014820500738 
27.  Lea OA, Kvinnsland S and Thorsen T (1989) Improved 
measurement of androgen receptors in human breast 
cancer Cancer Res 49 7162–7167 PMID: 2582456 
28.  Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, 
Look MP, Liem GS, Klijn JG and Henzen-Logmans SC 
(1996) The clinical significance of androgen receptors 
in breast cancer and their relation to histological and 
cell biological parameters Eur J Cancer 32A 1560–1565 
PMID: 8911118 doi:10.1016/0959-8049(96)00112-8 
29.  Agoff SN, Swanson PE, Linden H, Hawes SE and Lawton 
TJ (2003) Androgen receptor expression in estrogen 
receptor-negative breast cancer. 
Immunohistochemical, clinical, and prognostic 
associations.  Am J Clin Pathol  120 725–731  PMID: 
14608899  doi:10.1309/42F00D0DJD0J5EDT 
30.  Brys M, Wojcik M, Romanowicz-Makowska H and 
Krajewska WM (2002) Androgen receptor status in 
female breast cancer:RT-PCR and Western blot studies 
J Cancer Res Clin Oncol  128 85–90  PMID: 11862478   
doi:10.1007/s004320100294 
31.  Bieche I, Parfait B, Tozlu S, Lidereau R and Vidaud M 
(2001)  Quantitation of androgen receptor gene 
expression in sporadic breast tumours by real-time RT-
PCR:evidence that MYC is an AR-regulated gene 
Carcinogenesis  22 1521–1526  PMID: 11532875  doi: 
10.1093/carcin/22.9.1521 
32.  Gonzalez LO, Pidal I, Junquera S, Corte MD, Vazquez J, 
Rodriguez JC, Lamelas ML, Merino AM, Garcia-Muniz JL 
and Vizoso FJ (2007) Overexpression of matrix 
metalloproteinases and their inhibitors in mononuclear 
inflammatory cells in breast cancer correlates with 
metastasis-relapse  Br J Cancer  97 957–963  PMID: 
17848954  doi:10.1038/sj.bjc.6603935 
33.  Soreide JA, Lea OA, Varhaug JE, Skarstein A and 
Kvinnsland S (1992) Androgen receptors in operable 
breast cancer:relation to other steroid hormone 
receptors, correlations to prognostic factors and 
predictive value for effect of adjuvant tamoxifen 
treatment Eur J Surg Oncol 18 112–118 PMID: 1582503 
34.  Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter 
DJ, Spiegelman D, Barbieri RL and Speizer FE (1998) 
Plasma sex steroid hormone levels and risk of breast 
cancer in postmenopausal women J Natl Cancer Inst 90 
1292–1299 PMID: 9731736  doi:10.1093/jnci/90.17.1292 
35.  Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L et al (2005) 
Serum sex steroids in premenopausal women and 
breast cancer risk within the European Prospective 
Investigation into Cancer and Nutrition (EPIC)  J Natl 
Cancer Inst 97 755–765 PMID: 15900045 doi:10.1093/jnci/ 
dji132 
36.  Micheli A, Meneghini E, Secreto G, Berrino F, Venturelli E 
et al (2007) Plasma testosterone and prognosis of 
postmenopausal breast cancer patients J Clin Oncol 25 
2685–2690  PMID: 17548841  doi:10.1200/JCO.2006.09. 
0118 
37.  Wu K, DuPre E, Kim H, Tin U, Bissonnette RP, Lamph WW 
and Brown PH (2006) Receptor-selective retinoids 
inhibit the growth of normal and malignant breast cells 
by inducing G1 cell cycle blockade Breast Cancer Res 
Treat 96 147–157 PMID: 16273314  doi:10.1007/s10549-
005-9071-1 
38.  Pfahl M (1994) Vertebrate receptors:molecular biology, 
dimerization and response elements Semin Cell Biol 5 
95–103 PMID: 8068887 doi:10.1006/scel.1994.1013 
39.  Mangelsdorf DJ and Evans RM (1995) The RXR 
heterodimers and orphan receptors  Cell  83  841–850 
PMID: 8521508  doi:10.1016/0092-8674(95)90200-7 
40.  Germain P, Chambon P, Eichele G, Evans RM, Lazar MA 
et al (2006) International Union of Pharmacology. LX. 
Retinoic acid receptors. Pharmacol Rev  58 712–725 
PMID: 17132850  doi:10.1124/pr.58.4.4 
41.  Lotan R (1979) Different susceptibilities of human 
melanoma and breast carcinoma cell lines to retinoic 
acid-induced growth inhibition  Cancer Res  39 1014–
1019 PMID: 427741 
 9  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
42.  Toma S, Isnardi L, Raffo P, Dastoli G, De FE, Riccardi L, 
Palumbo R and Bollag W (1997) Effects of all-trans-
retinoic acid and 13-cis-retinoic acid on breast-cancer 
cell lines:growth inhibition and apoptosis induction Int 
J Cancer  70 619–627  PMID: 9052765  doi:10.1002/(SICI) 
1097-0215(19970304)70:53.0.CO;2-6 
43.  Bacus SS, Kiguchi K, Chin D, King CR and Huberman E 
(1990) Differentiation of cultured human breast cancer 
cells (AU-565 and MCF-7) associated with loss of cell 
surface HER-2/neu antigen  Mol Carcinog  3 350–362 
PMID: 1980588 doi:10.1002/mc.2940030607 
44.  van der Leede BM, Geertzema J, Vroom TM, Decimo D, 
Lutz Y, van der Saag PT and van der Burg B (1996) 
Immunohistochemical analysis of retinoic acid 
receptor-alpha in human breast tumours:retinoic acid 
receptor-alpha expression correlates with proliferative 
activity Am J Pathol 148 1905–1914 PMID: 8669476 
45.  Zhang XK, Liu Y and Lee MO (1996) Retinoid receptors 
in human lung cancer and breast cancer Mutat Res 350 
267–277 PMID: 8657191 
46.  Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ et al (1997) 
Progressive decrease in nuclear retinoic acid receptor 
beta messenger RNA level during breast 
carcinogenesis  Cancer Res  57 4992–4996  PMID: 
9371489 
47.  Grommes C, Landreth GE and Heneka MT (2004) 
Antineoplastic effects of peroxisome proliferator-
activated receptor gamma agonists Lancet Oncol 5 419–
429 PMID: 15231248  doi:10.1016/S1470-2045(04)01509-8 
48.  Koeffler HP (2003) Peroxisome proliferator-activated 
receptor gamma and cancers  Clin Cancer Res  9 1 –9 
PMID: 12538445 
49.  Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ et al 
(1998) Terminal differentiation of human breast cancer 
through PPAR gamma  Mol Cell  1 465–470 PMID: 
9660931  doi:10.1016/S1097-2765(00)80047-7 
50.  Fajas L, Debril MB and Auwerx J (2001) Peroxisome 
proliferator-activated receptor-gamma:from 
adipogenesis to carcinogenesis J Mol Endocrinol 27 1–9 
PMID: 11463572  doi:10.1677/jme.0.0270001 
51.  Murphy GJ and Holder JC (2000) PPAR-gamma 
agonists:therapeutic role in diabetes, inflammation and 
cancer  Trends Pharmacol Sci  21 469–474 PMID: 
11121836  doi:10.1016/S0165-6147(00)01559-5 
52.  Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E et al 
(2004) PPAR gamma signaling exacerbates mammary 
gland tumour development  Genes Dev  18 528–540 
PMID: 15037548  doi:10.1101/gad.1167804 
53.  Nunez NP, Liu H and Meadows GG (2006) PPAR-gamma 
ligands and amino acid deprivation promote apoptosis 
of melanoma, prostate, and breast cancer cells Cancer 
Lett  236 133–141 PMID: 15979236   doi:10.1016/j.canlet. 
2005.05.009 
54.  Papadaki I, Mylona E, Giannopoulou I, Markaki S, 
Keramopoulos A and Nakopoulou L (2005) PPARgamma 
expression in breast cancer:clinical value and 
correlation with ERbeta Histopathology 46 37–42 PMID: 
15656884  doi:10.1111/j.1365-2559.2005.02056.x 
55.  Veronesi U, De Palo G, Marubini E, Costa A, Formelli F et 
al (1999) Randomized trial of fenretinide to prevent 
second breast malignancy in women with early breast 
cancer J Natl Cancer Inst  91 1847–1856 PMID: 10547391 
 doi:10.1093/jnci/91.21.1847 
56.  Lefebvre MF, Guillot C, Crepin M and Saez S (1995) 
Influence of tumour derived fibroblasts and 1,25-
dihydroxyvitamin D3 on growth of breast cancer cell 
lines Breast Cancer Res Treat 33 189–197 PMID: 7749146 
 doi:10.1007/BF00665943 
57.  Simboli-Campbell M, Narvaez CJ, Tenniswood M and 
Welsh J (1996) 1,25-Dihydroxyvitamin D3 induces 
morphological and biochemical markers of apoptosis 
in MCF-7 breast cancer cells J Steroid Biochem Mol Biol 
58 367–376 PMID: 8903420  doi:10.1016/0960-0760(96) 
00055-6 
58.  Kanazawa T, Enami J and Kohmoto K (1999) Effects of 
1alpha,25-dihydroxycholecalciferol and cortisol on the 
growth and differentiation of primary cultures of mouse 
mammary epithelial cells in collagen gel Cell Biol Int 23 
481–487 PMID: 10728785  doi:10.1006/cbir.1999.0406 
59.  Narvaez CJ and Welsh J (2001) Role of mitochondria 
and caspases in vitamin D-mediated apoptosis of MCF-
7 breast cancer cells J Biol Chem 276 9101–9107 PMID: 
11053435 doi:10.1074/jbc.M006876200 
60.  Colston KW, Berger U and Coombes RC (1989) Possible 
role for vitamin D in controlling breast cancer cell 
proliferation  Lancet  1 188–191 PMID: 2563099 
doi:10.1016/S0140-6736(89)91204-X 
61.  Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT 
et al (1994) 1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-
hexafluorocholecalciferol (Ro24-5531), a new deltanoid 
(vitamin D analogue) for prevention of breast cancer in 
the rat Cancer Res 54 1653–1656 PMID: 8137276 
62.  Conde I, Paniagua R, Fraile B, Ruiz A and Arenas MI 
(2004) Expression of vitamin D3 receptor and retinoid 
receptors in human breast cancer:identification of 
potential heterodimeric receptors Int J Oncol 25 1183–
1191 PMID: 15375571 
63.  Friedrich M, Rafi L, Tilgen W, Schmidt W and Reichrath J 
(1998)  Expression of 1,25-dihydroxy vitamin D3 
receptor in breast carcinoma J Histochem Cytochem 46 
1335–1337 PMID: 9774633 
 10  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
64.  Berger U, McClelland RA, Wilson P, Greene GL, Haussler 
MR et al (1991) Immunocytochemical determination of 
estrogen receptor, progesterone receptor, and 1,25-
dihydroxyvitamin D3 receptor in breast cancer and 
relationship to prognosis Cancer Res 51 239–244 PMID: 
1846309 
65.  Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA 
and Willett WC (2002) Intake of dairy products, calcium, 
and vitamin d and risk of breast cancer J Natl Cancer 
Inst 94 1301–1311 PMID: 12208895 
66.  Knekt P, Jarvinen R, Seppanen R, Pukkala E and Aromaa 
A (1996) Intake of dairy products and the risk of breast 
cancer Br J Cancer 73 687–691 PMID: 8605108 
67.  John EM, Schwartz GG, Dreon DM and Koo J (1999) 
Vitamin D and breast cancer risk:the NHANES I 
Epidemiologic follow-up study, 1971-1975 to 1992. 
National Health and Nutrition Examination Survey 
Cancer Epidemiol Biomarkers Prev  8  399–406  PMID: 
10350434 
68.  Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA and 
Bundred NJ (1997) Serum 1,25-dihydroxyvitamin D may 
be related inversely to disease activity in breast cancer 
patients with bone metastases J Clin Endocrinol Metab 
82 118–122 PMID: 8989244  doi:10.1210/jc.82.1.118 
69.  Janowsky EC, Lester GE, Weinberg CR, Millikan RC, 
Schildkraut JM, Garrett PA and Hulka BS (1999) 
Association between low levels of 1,25-
dihydroxyvitamin D and breast cancer risk Public Health 
Nutr  2 283–291 PMID: 10512563  doi:10.1017/ 
S1368980099000385 
70.  Guyton KZ, Kensler TW and Posner GH (2003) Vitamin D 
and vitamin D analogs as cancer chemopreventive 
agents  Nutr Rev  61 227–238 PMID: 12918875 
doi:10.1301/nr.2003.jul.227-238 
71.  Andrechek ER and Muller WJ (2000) Tyrosine kinase 
signalling in breast cancer:tyrosine kinase-mediated 
signal transduction in transgenic mouse models of 
human breast cancer  Breast Cancer Res  2  211–216 
PMID: 11250712  doi:10.1186/bcr56 
72.  Blume-Jensen P and Hunter T (2001) Oncogenic kinase 
signalling  Nature  411  355–365  PMID: 11357143   
doi:10.1038/35077225 
73.  Gschwind A, Fischer OM and Ullrich A (2004) The 
discovery of receptor tyrosine kinases:targets for 
cancer therapy  Nat Rev Cancer  4 361–370 PMID: 
15122207  doi:10.1038/nrc1360 
74.  Nicholson RI, Gee JM and Harper ME (2001) EGFR and 
cancer prognosis  Eur J Cancer  37 Suppl 4 S9–15 
doi:10.1016/S0959-8049(01)00231-3 
75.  Holbro T, Civenni G and Hynes NE (2003) The ErbB 
receptors and their role in cancer progression Exp Cell 
Res  284  99–110  PMID: 12648469  doi:10.1016/S0014-
4827(02)00099-X 
76.  Klijn JG, Berns PM, Schmitz PI and Foekens JA (1992) 
The clinical significance of epidermal growth factor 
receptor (EGF-R) in human breast cancer:a review on 
5232 patients  Endocr Rev  13 3–17 PMID: 1313356 
doi:10.1210/er.13.1.3 
77.  Ethier SP (1995) Growth factor synthesis and human 
breast cancer progression J Natl Cancer Inst 87 964–973 
PMID: 7629883 doi:10.1093/jnci/87.13.964 
78.  van AT, Timmermans M, Foekens JA, Dorssers LC, 
Henzen-Logmans SC (1994) Differential expression of 
estrogen, progesterone, and epidermal growth factor 
receptors in normal, benign, and malignant human 
breast tissues using dual staining 
immunohistochemistry  Am J Pathol  144 1238–1246 
PMID: 7515559 
79.  Fabian CJ, Zalles C, Kamel S, Kimler BF, McKittrick R et al 
(1994)  Prevalence of aneuploidy, overexpressed ER, 
and overexpressed EGFR in random breast aspirates 
of women at high and low risk for breast cancer Breast 
Cancer Res Treat  30 263–274 PMID: 7981444  
doi:10.1007/BF00665967 
80.  Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and 
McGuire WL (1987) Human breast cancer:correlation of 
relapse and survival with amplification of the HER-
2/neu oncogene  Science  235  177–182  PMID: 3798106 
doi:10.1126/science.3798106 
81.  Ross JS and Fletcher JA (1998) The HER-2/neu 
Oncogene in Breast Cancer:Prognostic Factor, 
Predictive Factor, and Target for Therapy Oncologist 3 
237–252 PMID: 10388110 
82.  Ropero S, Menendez JA, Vazquez-Martin A, Montero S, 
Cortes-Funes H and Colomer R (2004) Trastuzumab plus 
tamoxifen:anti-proliferative and molecular interactions 
in breast carcinoma Breast Cancer Res Treat 86125–137 
PMID: 15319565  doi:10.1023/B:BREA.0000032981.20384. 
c6 
83.  Gago FE, Fanelli MA and Ciocca DR (2006) Co-
expression of steroid hormone receptors (estrogen 
receptor alpha and/or progesterone receptors) and 
Her2/neu (c-erbB-2) in breast cancer:clinical outcome 
following tamoxifen-based adjuvant therapy  J Steroid 
Biochem Mol Biol 98 36–40 PMID: 16188438  doi:10.1016/ 
j.jsbmb.2005.07.002 
84.  Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, 
Schwarz S and Brockhoff G (2008) Cytogenetic analysis 
of HER1/EGFR, HER2, HER3 and HER4 in 278 breast 
cancer patients  Breast Cancer Res  10  R2  PMID: 
18182100  doi:10.1186/bcr1843 
 11  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
85.  Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek 
W and Hynes NE (2000) Effects of oncogenic ErbB2 on 
G1 cell cycle regulators in breast tumour cells 
Oncogene 19 1647-1656 PMID: 10763821  doi:10.1038/sj. 
onc.1203470 
86.  Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X and 
Thor AD (2007) Downregulation of erbB3 abrogates 
erbB2-mediated tamoxifen resistance in breast cancer 
cells  Int J Cancer  120  1874–1882  PMID: 17266042   
doi:10.1002/ijc.22423 
87.  Kong A, Calleja V, Leboucher P, Harris A, Parker PJ and 
Larijani B (2008) HER2 oncogenic function escapes 
EGFR tyrosine kinase inhibitors via activation of 
alternative HER receptors in breast cancer cells PLoS 
ONE 3 e2881 PMID: 18682844  doi:10.1371/journal.pone. 
0002881 
88.  Witton CJ, Reeves JR, Going JJ, Cooke TG and Bartlett JM 
(2003)  Expression of the HER1-4 family of receptor 
tyrosine kinases in breast cancer J Pathol 200 290–297 
PMID: 12845624 doi:10.1002/path.1370 
89.  Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E 
and Czerwenka K (2003) Co-expression of ErbB-family 
members in human breast cancer:Her-2/neu is the 
preferred dimerization candidate in nodal-positive 
tumours Breast Cancer Res Treat 80:353–361 PMID: 
14503808  doi:10.1023/A:1024929522376 
90.  Fuchs IB, Siemer I, Buhler H, Schmider A, Henrich W, 
Lichtenegger W, Schaller G and Kuemmel S (2006) 
Epidermal growth factor receptor changes during 
breast cancer metastasis Anticancer Res 26 4397–4401 
PMID: 17201160 
91.  Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR 
and Cooke TG (2004) Outcome and human epidermal 
growth factor receptor (HER) 1-4 status in invasive 
breast carcinomas with proliferation indices evaluated 
by bromodeoxyuridine labelling  Breast Cancer Res  6 
R246–R251 PMID: 15084248 doi:10.1186/bcr783 
92.  Vogt U, Bielawski K, Schlotter CM, Bosse U, Falkiewicz B 
and Podhajska AJ (1998) Amplification of erbB-4 
oncogene occurs less frequently than that of erbB-2 in 
primary human breast cancer Gene 223 375–380 PMID: 
9858771  doi:10.1016/S0378-1119(98)00454-5 
93.  Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E et 
al (2001) Her4 mediates ligand-dependent 
antiproliferative and differentiation responses in 
human breast cancer cells Mol Cell Biol 21 4265–4275 
PMID: 11390655  doi:10.1128/MCB.21.13.4265-4275.2001 
94.  Moses HL, Yang EY and Pietenpol JA (1990) TGF-beta 
stimulation and inhibition of cell proliferation:new 
mechanistic insights  Cell  63 245–247 PMID: 2208284 
doi:10.1016/0092-8674(90)90155-8 
95.  Wakefield LM and Roberts AB (2002) TGF-beta 
signaling:positive and negative effects on 
tumourigenesis  Curr Opin Genet Dev  12 22–29 PMID: 
11790550 doi:10.1016/S0959-437X(01)00259-3 
96.  Derynck R, Akhurst RJ and Balmain A (2001) TGF-beta 
signaling in tumour suppression and cancer 
progression  Nat Genet  29 117–129 PMID: 11586292 
doi:10.1038/ng1001-117 
97.  Cohen MM, Jr (2003) TGF beta/Smad signaling system 
and its pathologic correlates Am J Med Genet A 116A 1–
10 PMID: 12476444  doi:10.1002/ajmg.a.10750 
98.  Yingling JM, Blanchard KL and Sawyer JS (2004) 
Development of TGF-beta signalling inhibitors for 
cancer therapy Nat Rev Drug Discov 3 1011–1022 PMID: 
15573100  doi:10.1038/nrd1580 
99.  Akhurst RJ (2006) Large- and small-molecule inhibitors 
of transforming growth factor-beta signalling Curr Opin 
Investig Drugs 7 513–521 PMID: 16784021 
100. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E et al 
(2007)  Ki26894, a novel transforming growth factor-
beta type I receptor kinase inhibitor, inhibits in vitro 
invasion and in vivo bone metastasis of a human 
breast cancer cell line  Cancer Sci  98 127–133 PMID: 
17129361 doi:10.1111/j.1349-7006.2006.00357.x 
101. Ge R, Rajeev V, Ray P, Lattime E, Rittling S et al (2006) 
Inhibition of growth and metastasis of mouse 
mammary carcinoma by selective inhibitor of 
transforming growth factor-beta type I receptor kinase 
in vivo Clin Cancer Res 12 4315–4330 PMID: 16857807  
doi:10.1158/1078-0432.CCR-06-0162 
102. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X et al 
(2006) Inhibition of pulmonary and skeletal metastasis 
by a transforming growth factor-beta type I receptor 
kinase inhibitor  Cancer Res  66 6714–6721 PMID: 
16818646 doi:10.1158/0008-5472.CAN-05-3565 
103. Wang Y, He QY, Chen H and Chiu JF (2007) Synergistic 
effects of retinoic acid and tamoxifen on human breast 
cancer cells:proteomic characterization  Exp Cell Res 
313 357–368 PMID: 17098229  doi:10.1016/j.yexcr.2006. 
10.016 
104. Yu H and Rohan T (2000) Role of the insulin-like growth 
factor family in cancer development and progression J 
Natl Cancer Inst   92 1472–1489 PMID: 10995803  
doi:10.1093/jnci/92.18.1472 
105. Pollak M (1998) IGF-I physiology and breast cancer 
Recent Results Cancer Res 152 63–70 PMID: 9928547 
106. Surmacz E (2000) Function of the IGF-I receptor in 
breast cancer J Mammary Gland Biol Neoplasia 5 95–105 
PMID: 10791772  doi:10.1023/A:1009523501499 
 12  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
107. Sachdev D and Yee D (2007) Disrupting insulin-like 
growth factor signaling as a potential cancer therapy 
Mol Cancer Ther  6 1–12 PMID: 17237261  doi:10.1158/ 
1535-7163.MCT-06-0080 
108. Baxter RC (2001) Signalling pathways involved in 
antiproliferative effects of IGFBP-3:a review Mol Pathol 
54 145–148 PMID: 11376125  doi:10.1136/mp.54.3.145 
109. Martin JL and Baxter RC (1991) Transforming growth 
factor-beta stimulates production of insulin-like growth 
factor-binding protein-3 by human skin fibroblasts 
Endocrinology  128 1425–1433 PMID: 1705505  doi: 
10.1210/endo-128-3-1425 
110. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie 
JM and Cohen P (2000) Direct functional interactions 
between insulin-like growth factor-binding protein-3 
and retinoid X receptor-alpha regulate transcriptional 
signaling and apoptosis J Biol Chem 275 33607–33613 
PMID: 10874028 doi:10.1074/jbc.M002547200 
111. Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L et 
al (2003) Relationships between plasma insulin-like 
growth factor-I and insulin-like growth factor binding 
protein-3 and second breast cancer risk in a prevention 
trial of fenretinide Clin Cancer Res 9 4722–4729 
112. Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ 
(2004)  COX-2 expression is associated with an 
aggressive phenotype in ductal carcinoma in situ Br J 
Cancer  90 423–429 PMID: 14735188  doi:10.1038/sj.bjc. 
6601534 
113. Shim JY, An HJ, Lee YH, Kim SK, Lee KP and Lee KS 
(2003)  Overexpression of cyclooxygenase-2 is 
associated with breast carcinoma and its poor 
prognostic factors  Mod Pathol  16 1199–1204 PMID: 
14681319  doi:10.1097/01.MP.0000097372.73582.CB 
114. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M et al 
(2003)  Correlation of COX-2 and Ep-CAM 
overexpression in human invasive breast cancer and 
its impact on survival  Br J Cancer  88 574–578 PMID: 
12592372  doi:10.1038/sj.bjc.6600741 
115. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C et al 
(2003)  Analysis of cyclooxygenase-2 expression in 
human breast cancer:high throughput tissue 
microarray analysis J Cancer Res Clin Oncol 129 375–
382 PMID: 12884024  doi:10.1007/s00432-003-0459-1 
116. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, 
Haglund C, Joensuu H and Isola J (2002) Prognostic 
significance of elevated cyclooxygenase-2 expression 
in breast cancer  Cancer Res  62  632–635  PMID: 
11830510 
117. Subbaramaiah K, Norton L, Gerald W and Dannenberg AJ 
(2002)  Cyclooxygenase-2 is overexpressed in HER-
2/neu-positive breast cancer:evidence for involvement 
of AP-1 and PEA3 J Biol Chem 27718649–18657 PMID: 
11901151  doi:10.1074/jbc.M111415200 
118. Cotterchio M, Kreiger N, Sloan M and Steingart A (2001) 
Nonsteroidal anti-inflammatory drug use and breast 
cancer risk Cancer Epidemiol Biomarkers Prev 10 1213–
1217 PMID: 11700271 
119. Khuder SA and Mutgi AB (2001) Breast cancer and 
NSAID use:a meta-analysis Br J Cancer 84 1188–1192 
PMID: 11336469  doi:10.1054/bjoc.2000.1709 
120. Harris RE, Beebe-Donk J and Alshafie GA (2006) 
Reduction in the risk of human breast cancer by 
selective cyclooxygenase-2 (COX-2) inhibitors  BMC 
Cancer 6 27 PMID: 16445867 doi:10.1186/1471-2407-6-27 
121. Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C 
et al (2003) The cyclooxygenase-2 inhibitor, celecoxib, 
prevents the development of mammary tumours in Her-
2/neu mice  Cancer Epidemiol Biomarkers Prev 121486–
1491 PMID: 14693742 
122. Alshafie GA, bou-Issa HM, Seibert K and Harris RE (2000) 
Chemotherapeutic evaluation of Celecoxib, a 
cyclooxygenase-2 inhibitor, in a rat mammary tumour 
model Oncol Rep 7 1377–1381 PMID: 11032948 
123. Grosser T, Fries S and FitzGerald GA (2006) Biological 
basis for the cardiovascular consequences of COX-2 
inhibition:therapeutic challenges and opportunities  J 
Clin Invest  116 4–15 PMID: 16395396  doi:10.1172/ 
JCI27291 
124. Sauter ER, Qin W, Schlatter L, Hewett JE and Flynn JT 
(2006)  Celecoxib decreases prostaglandin E2 
concentrations in nipple aspirate fluid from high risk 
postmenopausal women and women with breast 
cancer BMC Cancer 6 248 PMID: 17049084 doi:10.1186/ 
1471-2407-6-248 
125. Hojilla CV, Wood GA and Khokha R (2008) Inflammation 
and breast cancer: metalloproteinases as common 
effectors of inflammation and extracellular matrix 
breakdown in breast cancer Breast Cancer Res 10 205 
PMID: 18394187 doi:10.1186/bcr1980 
126. Hojilla CV, Mohammed FF and Khokha R (2003) Matrix 
metalloproteinases and their tissue inhibitors direct 
cell fate during cancer development  Br J Cancer  89 
1817–1821 PMID: 14612884 doi:10.1038/sj.bjc.6601327 
127. Li HC, Cao DC, Liu Y, Hou YF, Wu J et al (2004) 
Prognostic value of matrix metalloproteinases (MMP-2 
and MMP-9) in patients with lymph node-negative 
breast carcinoma  Breast Cancer Res Treat  88  75–85 
PMID: 15538048  doi:10.1007/s10549-004-1200-8 
128. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, 
Eskelinen MJ and Kosma VM (2004) Expression of matrix 
metalloproteinase (MMP)-2 and MMP-9 in breast cancer 
 13  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
with a special reference to activator protein-2, HER2, 
and prognosis  Clin Cancer Res  10 7621–7628 PMID: 
15569994  doi:10.1158/1078-0432.CCR-04-1061 
129. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, 
Abraham J and Leffall LD (2005) Identification of MMP-1 
as a putative breast cancer predictive marker by global 
gene expression analysis  Nat Med  11 481–483 PMID: 
15864312  doi:10.1038/nm1243 
130. Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, 
Brown-Shimer S, Pierce K and Carney W (2007) Elevated 
plasma tissue inhibitor of metalloproteinase-1 level 
predicts decreased response and survival in metastatic 
breast cancer  Cancer  109 1933–1939 PMID: 17407159 
doi:10.1002/cncr.22637 
131. Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, 
Heuvel JJ, Beex LV and Sweep CG (2004) Tissue 
inhibitors of metalloproteinase expression in human 
breast cancer:TIMP-3 is associated with adjuvant 
endocrine therapy success J Pathol 202 395–402 PMID: 
15095266 doi:10.1002/path.1528 
132. Edwards DR (2004) TIMP-3 and endocrine therapy of 
breast cancer: an apoptosis connection emerges  J 
Pathol 202 391–394 doi:10.1002/path.1548 
133. Kotzsch M, Farthmann J, Meye A, Fuessel S, Baretton G et 
al (2005) Prognostic relevance of uPAR-del4/5 and 
TIMP-3 mRNA expression levels in breast cancer Eur J 
Cancer  41  2760–2768  PMID: 16256342   doi:10.1016/j. 
ejca.2005.09.002 
134. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell 
E, Khokha R and Boyd NF (2001) Growth factors and 
stromal matrix proteins associated with 
mammographic densities  Cancer Epidemiol Biomarkers 
Prev 10 243–248 PMID: 11303594 
135. Mochizuki S and Okada Y (2007) ADAMs in cancer cell 
proliferation and progression  Cancer Sci  98 621–628 
PMID: 17355265 doi:10.1111/j.1349-7006.2007.00434.x 
136. Arribas J, Bech-Serra JJ and Santiago-Josefat B (2006) 
ADAMs, cell migration and cancer  Cancer  Metastasis 
Rev  25  57–68  PMID: 16680572  doi:10.1007/s10555-006-
7889-6 
137. Gabay C and Kushner I (1999) Acute-phase proteins and 
other systemic responses to inflammation N Engl J Med 
340 448–454 PMID: 9971870  doi:10.1056/ 
NEJM199902113400607 
138. Robertson JF, Pearson D, Price MR, Selby C, Pearson J, 
Blamey RW and Howell A (1991) Prospective 
assessment of the role of five tumour markers in breast 
cancer  Cancer Immunol Immunother  33  403–410  PMID: 
1878893 doi:10.1007/BF01741602 
139. Mortensen RF and Rudczynski AB (1982) Prognostic 
significance of serum CRP levels and lymphoid cell 
infiltrates in human breast cancer Oncology 39 129–133 
PMID: 7078935 doi:10.1159/000225621 
140. Albuquerque KV, Price MR, Badley RA, Jonrup I, Pearson 
D, Blamey RW and Robertson JF (1995) Pre-treatment 
serum levels of tumour markers in metastatic breast 
cancer:a prospective assessment of their role in 
predicting response to therapy and survival Eur J Surg 
Oncol  21 504–509 PMID: 7589594  doi:10.1016/S0748-
7983(95)96935-7 
141. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone 
J and McArdle CS (2001) Measurement of the systemic 
inflammatory response predicts cancer-specific and 
non-cancer survival in patients with cancer Nutr Cancer 
41 64–69 PMID: 12094630 doi:10.1207/S15327914NC41-
1&2_8 
142. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson 
C and McMillan DC (2006) Evaluation of an 
inflammation-based prognostic score (GPS) in patients 
with metastatic breast cancer Br J Cancer 94 227–230 
PMID: 16404432  doi:10.1038/sj.bjc.6602922 
143. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman 
JC et al (2006) C-reactive protein levels, variation in the 
C-reactive protein gene, and cancer risk: the Rotterdam 
Study  J Clin Oncol  24 5216–5222 PMID: 17114654   
doi:10.1200/JCO.2006.07.1381 
144. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC 
et al (2005) Circulating levels of inflammatory markers 
and cancer risk in the health aging and body 
composition cohort  Cancer Epidemiol Biomarkers Prev 
14 2413–2418 PMID: 16214925  doi:10.1158/1055-
9965.EPI-05-0316 
145. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A 
and Boffetta P (2006) Plasma C-reactive protein and risk 
of cancer: a prospective study from Greece  Cancer 
Epidemiol Biomarkers Prev 15 381–384 PMID: 16492932  
doi:10.1158/1055-9965.EPI-05-0626 
146. Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE 
and Ridker PM (2007) C-reactive protein and risk of 
breast cancer  J Natl Cancer Inst  99  890–894  PMID: 
17551149 doi:10.1093/jnci/djk202 
147. Lithgow D, Nyamathi A, Elashoff D, Martinez-Maza O and 
Covington C (2007) C-reactive protein in nipple aspirate 
fluid associated with Gail model factors Biol Res Nurs 9 
108–116 PMID: 17909163 doi:10.1177/1099800407306426 
148. Tuck AB, Chambers AF and Allan AL (2007) Osteopontin 
overexpression in breast cancer: knowledge gained 
and possible implications for clinical management  J 
Cell Biochem  102 859–868 PMID: 17721886   
doi:10.1002/jcb.21520 
 14  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
149. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, 
Kerkvliet N, Saad Z, Doig GS and Chambers AF (1998) 
Osteopontin expression in a group of lymph node 
negative breast cancer patients Int J Cancer 79 502–508 
PMID: 9761120  doi:10.1002/(SICI)1097-0215(19981023) 
79:53.0.CO;2-3 
150. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva RS et 
al (2002) Prognostic significance of the metastasis-
associated protein osteopontin in human breast cancer 
Cancer Res 62 3417–3427 PMID: 12067984 
151. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, 
Pestano GA, He B and Weber GF (2008) Osteopontin-c is 
a selective marker of breast cancer  Int J Cancer  122 
889–897 PMID: 17960616 doi:10.1002/ijc.23204 
152. Patani N, Jouhra F, Jiang W and Mokbel K (2008) 
Osteopontin expression profiles predict pathological 
and clinical outcome in breast cancer Anticancer Res 28 
4105–4110 PMID: 19192668 
153. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS et 
al (2006) Serial plasma osteopontin levels have 
prognostic value in metastatic breast cancer  Clin 
Cancer Res 12 3337–3343 PMID: 16740755 doi:10.1158/ 
1078-0432.CCR-05-2354 
154. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB 
et al (1997) Elevated plasma osteopontin in metastatic 
breast cancer associated with increased tumour 
burden and decreased survival Clin Cancer Res 3 605–
611 PMID: 9815727 
155. Salvesen GS and Duckett CS (2002) IAP 
proteins:blocking the road to death's door Nat Rev Mol 
Cell Biol 3 401–410 PMID: 12042762 doi:10.1038/nrm830 
156. Altieri DC (2003) Validating survivin as a cancer 
therapeutic target  Nat Rev Cancer  3 46–54 PMID: 
12509766  doi:10.1038/nrc968 
157. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J et al 
(1999) Analysis of human transcriptomes Nat Genet 23 
387–388 PMID: 10581018 doi:10.1038/70487 
158. Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y et al 
(2005)  A potent immunogenic general cancer vaccine 
that targets survivin, an inhibitor of apoptosis proteins 
Clin Cancer Res  11 1474–1482 PMID: 15746049   
doi:10.1158/1078-0432.CCR-03-0817 
159. Paik S, Shak S, Tang G, Kim C, Baker J et al (2004) A 
multigene assay to predict recurrence of tamoxifen-
treated, node-negative breast cancer N Engl J Med 351 
2817–2826 PMID: 15591335 doi:10.1056/NEJMoa041588 
160. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T et 
al (2006) Persistent activation of stat3 signaling 
induces survivin gene expression and confers 
resistance to apoptosis in human breast cancer cells 
Clin Cancer Res 12 11–19 PMID: 16397018 doi:10.1158/ 
1078-0432.CCR-04-1752 
161. Xia W, Bisi J, Strum J, Liu L, Carrick K et al (2006) 
Regulation of survivin by ErbB2 signaling:therapeutic 
implications for ErbB2-overexpressing breast cancers 
Cancer Res 66 1640–1647 PMID: 16452223  doi:10.1158/ 
0008-5472.CAN-05-2000 
162. Chu JS, Shew JY and Huang CS (2004) 
Immunohistochemical analysis of survivin expression 
in primary breast cancers J Formos Med Assoc 103 925–
931 PMID: 15624042 
163. Kayaselcuk F, Nursal TZ, Polat A, Noyan T, Yildirim S, 
Tarim A and Seydioglu G (2004) Expression of survivin, 
bcl-2, P53 and bax in breast carcinoma and ductal 
intraepithelial neoplasia (DIN 1a) J Exp Clin Cancer Res 
23 105–112 PMID: 15149158 
164. Goksel G, Taneli F, Uslu R, Ulman C, Dinc G, Coskun T 
and Kandiloglu AR (2007) Serum her-2/neu and survivin 
levels and their relationship to histological parameters 
in early-stage breast cancer J Int Med Res 35 165–172 
PMID: 17542404 
165. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M et al 
(2006)  Survivin expression in breast cancer predicts 
clinical outcome and is associated with HER2, VEGF, 
urokinase plasminogen activator and PAI-1 Ann Oncol 
17 597–604 PMID: 16403812 doi:10.1093/annonc/mdj121 
166. Hinnis AR, Luckett JC and Walker RA (2007) Survivin is 
an independent predictor of short-term survival in poor 
prognostic breast cancer patients Br J Cancer 96 639–
645 PMID: 17285125 doi:10.1038/sj.bjc.6603616 
167. Vousden KH and Lu X (2002) Live or let die:the cell's 
response to p53  Nat Rev Cancer  2  594–604  PMID: 
12154352  doi:10.1038/nrc864 
168. Vogelstein B, Lane D and Levine AJ (2000) Surfing the 
p53 network  Nature  408 307–310 PMID: 11099028   
doi:10.1038/35042675 
169. Miller LD, Smeds J, George J, Vega VB, Vergara L et al 
(2005) An expression signature for p53 status in human 
breast cancer predicts mutation status, transcriptional 
effects, and patient survival Proc Natl Acad Sci USA 102 
13550–13555  PMID: 16141321  doi:10.1073/pnas. 
0506230102 
170. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S et al 
(2006)  The clinical value of somatic TP53 gene 
mutations in 1,794 patients with breast cancer  Clin 
Cancer Res 12 1157–1167 PMID: 16489069 doi:10.1158/ 
1078-0432.CCR-05-1029 
171. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, 
Sutherland DA et al (2004) The combination of p53 
mutation and neu/erbB-2 amplification is associated 
 15  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
with poor survival in node-negative breast cancer J Clin 
Oncol  22  86–96  PMID: 14701769  doi:10.1200/JCO. 
2004.09.128 
172. Muller M, Meyer M, Schilling T, Ulsperger E, Lehnert T et al 
(2006)  Testing for anti-p53 antibodies increases the 
diagnostic sensitivity of conventional tumour markers 
Int J Oncol 29 973–980 PMID: 16964393 
173. Lenner P, Wiklund F, Emdin SO, Arnerlov C, Eklund C, 
Hallmans G, Zentgraf H and Dillner J (1999) Serum 
antibodies against p53 in relation to cancer risk and 
prognosis in breast cancer:a population-based 
epidemiological study  Br J Cancer  79 927–932 PMID: 
10070892 doi:10.1038/sj.bjc.6690148 
174. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L 
et al (1994) The relationship between serum p53 
autoantibodies and characteristics of human breast 
cancer Br J Cancer 69 1115–1119 PMID: 8198980 
175. Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN and Wang L 
(2005) The presence of serum anti-p53 antibodies from 
patients with invasive ductal carcinoma of 
breast:correlation to other clinical and biological 
parameters Breast Cancer Res Treat 93 111–115 PMID: 
16187230 doi:10.1007/s10549-005-4321-9 
176. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, 
Bluth RF et al (1995) Overexpression of cyclin D mRNA 
distinguishes invasive and in situ breast carcinomas 
from non-malignant lesions Nat Med 1 1257–1260 PMID: 
7489405 doi:10.1038/nm1295-1257 
177. Simpson JF, Quan DE, O'Malley F, Odom-Maryon T and 
Clarke PE (1997) Amplification of CCND1 and 
expression of its protein product, cyclin D1, in ductal 
carcinoma in situ of the breast Am J Pathol 151 161–168 
PMID: 9212742 
178. Gillett CE, Lee AH, Millis RR and Barnes DM (1998) Cyclin 
D1 and associated proteins in mammary ductal 
carcinoma in situ and atypical ductal hyperplasia  J 
Pathol  184 396–400 PMID: 9664905  doi:10.1002/(SICI) 
1096-9896(199804)184:43.0.CO;2-G 
179. Gillett C, Smith P, Gregory W, Richards M, Millis R et al 
(1996) Cyclin D1 and prognosis in human breast cancer 
Int J Cancer  69 92–99 PMID: 8608989  doi:10.1002/ 
(SICI)1097-0215(19960422)69:23.0.CO;2-Q 
180. Hwang TS, Han HS, Hong YC, Lee HJ and Paik NS (2003) 
Prognostic value of combined analysis of cyclin D1 
and estrogen receptor status in breast cancer patients 
Pathol Int 53 74–80 PMID: 12588434 doi:10.1046/j.1440-
1827.2003.01441.x 
181. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ et al 
(1997)  Cyclin D1 stimulation of estrogen receptor 
transcriptional activity independent of cdk4  Mol Cell 
Biol 17 5338–5347 PMID: 9271411 
182. Zhou Q, Stetler-Stevenson M and Steeg PS (1997) 
Inhibition of cyclin D expression in human breast 
carcinoma cells by retinoids in vitro Oncogene 15 107–
115 PMID: 9233783 doi:10.1038/sj.onc.1201142 
183. Kim HT, Kong G, Denardo D, Li Y, Uray I et al (2006) 
Identification of biomarkers modulated by the rexinoid 
LGD1069 (bexarotene) in human breast cells using 
oligonucleotide arrays  Cancer Res  6612009–12018. 
PMID: 17178900 doi:10.1158/0008-5472.CAN-05-2515 
184. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T et 
al (2006) Fifteen-year results of a randomized phase III 
trial of fenretinide to prevent second breast cancer Ann 
Oncol  17 1065–1071 PMID: 16675486   doi:10.1093/ 
annonc/mdl047 
185. Banerjee S, Dowsett M, Ashworth A and Martin LA (2007) 
Mechanisms of disease:angiogenesis and the 
management of breast cancer  Nat Clin Pract Oncol 4 
536–550 PMID: 17728712 doi:10.1038/ncponc0905 
186. Linderholm B, Grankvist K, Wilking N, Johansson M, 
Tavelin B and Henriksson R (2000) Correlation of 
vascular endothelial growth factor content with 
recurrences, survival, and first relapse site in primary 
node-positive breast carcinoma after adjuvant 
treatment J Clin Oncol 18 1423–1431 PMID: 10735889 
187. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K 
et al (2000) Vascular endothelial growth factor (VEGF) 
in breast cancer:comparison of plasma, serum, and 
tissue VEGF and microvessel density and effects of 
tamoxifen Cancer Res 60 2898–2905 PMID: 10850435 
188. Heer K, Kumar H, Read JR, Fox JN, Monson JR and Kerin 
MJ (2001) Serum vascular endothelial growth factor in 
breast cancer:its relation with cancer type and 
estrogen receptor status Clin Cancer Res 7 3491–3494 
PMID: 11705867 
189. Wu Y, Saldana L, Chillar R and Vadgama JV (2002) 
Plasma vascular endothelial growth factor is useful in 
assessing progression of breast cancer post surgery 
and during adjuvant treatment Int J Oncol 20 509–516 
PMID: 11836562 
190. Hieken TJ, Farolan M, D'Alessandro S and Velasco JM 
(2001)  Predicting the biologic behavior of ductal 
carcinoma in situ:an analysis of molecular markers 
Surgery  130 593–600 PMID: 11602889  doi:10.1067/msy. 
2001.116921 
191. Pavlakis K, Messini I, Vrekoussis T, Yiannou P, 
Keramopoullos D et al (2008) The assessment of 
angiogenesis and fibroblastic stromagenesis in 
hyperplastic and pre-invasive breast lesions  BMC 
Cancer 8 88 PMID: 18384688 doi:10.1186/1471-2407-8-88 
192. Hyder SM (2006) Sex-steroid regulation of vascular 
endothelial growth factor in breast cancer Endocr Relat 
 16  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:157 
 
Cancer  13 667–687 PMID: 16954424  doi:10.1677/erc. 
1.00931 
193. Garvin S, Nilsson UW, Dabrosin C. (2005) Effects of 
oestradiol and tamoxifen on VEGF, soluble VEGFR-1, 
and VEGFR-2 in breast cancer and endothelial cells. Br 
J Cancer 93:1005–1010. PMID: 16234819  doi:10.1038/sj. 
bjc.6602824 
194. Beresford MJ, Wilson GD and Makris A (2006) Measuring 
proliferation in breast cancer:practicalities and 
applications Breast Cancer Res 8 216 PMID: 17164010 
doi:10.1186/bcr1618 
195. Clayton F (1991) Pathologic correlates of survival in 378 
lymph node-negative infiltrating ductal breast 
carcinomas. Mitotic count is the best single predictor 
Cancer 68 1309–1317 PMID: 1651805  doi:10.1002/1097-
0142(19910915)68:63.0.CO;2-I 
196. van Diest PJ, van der WE and Baak JP (2004) Prognostic 
value of proliferation in invasive breast cancer:a review 
J Clin Pathol 57 675–681 PMID: 15220356  doi:10.1136/ 
jcp.2003.010777 
197. Barnard NJ, Hall PA, Lemoine NR and Kadar N (1987) 
Proliferative index in breast carcinoma determined in 
situ by Ki67 immunostaining and its relationship to 
clinical and pathological variables J Pathol 152 287–295 
PMID: 3668731  doi:10.1002/path.1711520407 
198. Parrado C, Falkmer UG, Hoog A, Falkmer S, Ahrens O, 
Rius F and Grimelius L (1996) A technique for 
automatic/interactive assessment of the proliferating 
fraction of neoplastic cells in solid tumours. A 
methodological study on the Ki-67 immunoreactive 
cells in human mammary carcinomas, including a 
comparison with the results of conventional S-phase 
fraction assessments by means of DNA cytometry Gen 
Diagn Pathol 141 215–227 PMID: 8705786 
199. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q et al 
(1997)  Ki-67 immunostaining in 322 primary breast 
cancers:associations with clinical and pathological 
variables and prognosis Int J Cancer 74 433–437. PMID: 
9291434  doi:10.1002/(SICI)1097-0215(19970822)74:43.0. 
CO;2-A 
200. Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie 
SR, Volovics A, Schouten HC and Hillen HF (1998) MIB-1 
labelling index is an independent prognostic marker in
primary breast cancer  Br J Cancer  78 460–465 PMID: 
9716027 
201. Goodson WH, III, Moore DH, Ljung BM, Chew K, Mayall B, 
Smith HS and Waldman FM (2000) The prognostic value 
of proliferation indices: a study with in vivo 
bromodeoxyuridine and Ki-67 Breast Cancer Res Treat 
59 113–123 PMID: 10817346  doi:10.1023/A: 
1006344010050 
202. Clarke RB, Laidlaw IJ, Jones LJ, Howell A and Anderson E 
(1993)  Effect of tamoxifen on Ki67 labelling index in 
human breast tumours and its relationship to 
oestrogen and progesterone receptor status  Br J 
Cancer 67 606–611 PMID: 8439511 
203. Johnston SR, MacLennan KA, Sacks NP, Salter J, Smith IE 
and Dowsett M (1994) Modulation of Bcl-2 and Ki-67 
expression in oestrogen receptor-positive human 
breast cancer by tamoxifen  Eur J Cancer  30A  1663–
1669 PMID: 7833141 doi:10.1016/0959-8049(94)00327-2 
204. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, 
Titley JC and Dowsett M (1998) Changes in hormone 
receptors and proliferation markers in tamoxifen 
treated breast cancer patients and the relationship with 
response  Breast Cancer Res Treat  48  11–20  PMID: 
9541185 doi:10.1023/A:1005973529921 
205. The ATAC (Arimidex TaoiCTG) (2002) Anastrozole alone 
or in combination with tamoxifen versus tamoxifen 
alone for adjuvant treatment of postmenopausal 
women with early breast cancer: first results of the 
ATAC randomised trial  Lancet  359  2131–2139  PMID: 
12090977 doi:10.1016/S0140-6736(02)09088-8 
206. Cazzaniga M, Severi G, Casadio C, Chiapparini L, 
Veronesi U and Decensi A (2006) Atypia and Ki-67 
expression from ductal lavage in women at different 
risk for breast cancer Cancer Epidemiol Biomarkers Prev 
15  1311–1315  PMID: 16835329  doi:10.1158/1055-9965. 
EPI-05-0810 
207. Khan QJ, Kimler BF, Clark J, Metheny T, Zalles CM and 
Fabian CJ (2005) Ki-67 expression in benign breast 
ductal cells obtained by random periareolar fine needle 
aspiration Cancer Epidemiol Biomarkers Prev 14 786–789 
PMID: 15824144  doi:10.1158/1055-9965.EPI-04-0239 
208. Sullivan RP, Mortimer G and Muircheartaigh IO (1993) Cell 
proliferation in breast tumours:analysis of histological 
parameters Ki67 and PCNA expression Ir J Med Sci 162 
343–347 PMID: 7903289 doi:10.1007/BF02942162 
 17  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 